arrow
V

Véronique Dartois

hackensack meridian health
H指数:72
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lesion penetration predicts tuberculosis treatment shortening through a validated translational tool to de-risk development

病灶穿透通过验证的转化工具预测结核病治疗缩短以降低开发风险

2026-10-140
OAAI
Design; Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis

设计;哌嗪基生物A抑制剂的合成与生物评价:靶向结核分枝杆菌生物素生物合成

2026-04-220
PRE
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis

用于治疗结核病的新型毒性降低的恶唑烷酮的发现和开发

2026-01-130
OAAI
PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes

不同药物治疗方案下卷尾猴结核肺病变的PET/CT成像结果与人类临床结局一致

2026-01-070
PRE
The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance

贝达喹啉在结核空洞中的扩散动力学为耐药性的出现提供了窗口

2025-06-010
OAAI
Next- generation rifamycins for the treatment of mycobacterial infections

下一代利福霉素用于分枝杆菌感染的治疗

2025-05-010
OA
Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly

靶向分枝杆菌酸细胞壁组装的定制苯基脲可消除耐药性结核分枝杆菌。

2025-01-010
OA
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis
2024-11-060
OAAI
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
2024-04-062
PRE
Inhibitors of the Thioesterase Activity of Mycobacterium tuberculosis Pks13 Discovered Using DNA-Encoded Chemical Library Screening
2024-04-052
OAAI